title: Transplantation tolerance: Clinical potential of regulatory T cells.
abstract: The major challenge in transplantation medicine remains long-term allograft acceptance, with preserved allograft function under minimal chronic immunosuppression. To safely achieve the goal of sustained donor-specific T and B cell non-responsiveness, research efforts are now focusing on therapies based on cell subsets with regulatory properties. In particular the transfusion of human regulatory T cells (Treg) is currently being evaluated in phase I/II clinical trials for the treatment of graft versus host disease following hematopoietic stem cell transplantation, and is also under consideration for solid organ transplantation. The purpose of this review is to recapitulate current knowledge on naturally occurring as well as induced human Treg, with emphasis on their specific phenotype, suppressive function and how these cells can be manipulated in vitro and/or in vivo for therapeutic purposes in transplantation medicine. We highlight the potential but also possible limitations of Treg-based strategies to promote long-term allograft survival. It is evident that the bench-to-beside translation of these protocols still requires further understanding of Treg biology. Nevertheless, current data already suggest that Treg therapy alone will not be sufficient and needs to be combined with other immunomodulatory approaches in order to induce allograft tolerance.
authors.affiliation: Surgical Research Unit; Department of Surgery; University Hospital Geneva.
authors.forename: Yannick D
authors.initials: YD
authors.lastname: Muller
authors.forename: Jörg D
authors.initials: JD
authors.lastname: Seebach
authors.forename: Leo H
authors.initials: LH
authors.lastname: Bühler
authors.forename: Manuel
authors.initials: M
authors.lastname: Pascual
authors.forename: Dela
authors.initials: D
authors.lastname: Golshayan